Research ArticleAlzheimer’s Disease

Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy

See allHide authors and affiliations

Science Translational Medicine  25 Jan 2017:
Vol. 9, Issue 374, eaag0481
DOI: 10.1126/scitranslmed.aag0481

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Stemming the tide of tauopathy

Accumulation of the protein tau directly correlates with cognitive decline in Alzheimer’s disease and other primary tauopathies. One therapeutic option may be to reduce total tau. In a new study, DeVos et al. identified antisense oligonucleotides (ASOs) that decreased human tau in the brains of transgenic mice with tauopathy and observed the reversal of preexisting tau pathology and tau seeding activity. Further, neuronal loss was halted and mouse survival extended. In monkeys, tau ASOs reduced tau in the brain and cerebrospinal fluid. Together, these data support investigating lowering tau in human patients who have tau-positive inclusions even after pathological tau has begun to be deposited.

View Full Text

Stay Connected to Science Translational Medicine